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Stability of Diluted Adenosine Solutions in Polyolefin Infusion Bags
Abstract
Background
Intravenous or intracoronary adenosine is used in the cardiac catherization lab to achieve maximal
coronary blood flow and determine fractional flow reserve.
Objective
To determine the stability of adenosine 10 and 50 µg/mL in either 0.9% sodium chloride injection or 5%
dextrose injection in polyolefin infusion bags stored at 2 temperatures, refrigeration (2°C-8°C) or
controlled room temperature (20°C-25°C).
Methods
Adenosine 10 µg/mL and 50 µg/mL solutions were prepared in 50 mL polyolefin infusion bags containing
0.9% sodium chloride injection or 5% dextrose injection and stored at controlled room temperature or
under refrigeration. Each combination of concentration, diluent, and storage was prepared in triplicate.
Samples were assayed using stability-indicating, reversed-phase high-performance liquid chromatography
immediately at time 0 and at 24 hours, 48 hours, 7 days, and 14 days. Stability was defined as retaining
90% to 110% of the initial adenosine concentration. The samples were also visually inspected against a
light background for clarity, color, and the presence of particulate matter.
Results
After 14 days, all samples retained 99% to 101% of the initial adenosine concentration. No considerable
change in pH or visual appearance was noted. The stability data indicated no significant loss of drug due
to chemical degradation or physical interactions during storage.
Conclusion
Adenosine solutions of 10 and 50 µg/mL were stable for at least 14 days in 50 mL polyolefin infusion
bags of 0.9% sodium chloride injection or 5% dextrose injection stored at controlled room temperature
and refrigerated conditions.
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BACKGROUND
Intravenous or intracoronary adenosine is used in the cardiac catherization lab to achieve
maximal coronary blood flow and determine fractional flow reserve.
OBJECTIVE
To determine the stability of adenosine 10 and 50 µg/mL in either 0.9% sodium chloride
injection or 5% dextrose injection in polyolefin infusion bags stored at two temperatures,
refrigeration (2 - 8°C) or at controlled room temperature (20 - 25°C).
METHODS
Adenosine 10 µg/mL and 50 µg/mL solutions were prepared in 50 mL polyolefin infusion
bags containing 0.9% sodium chloride injection or 5% dextrose injection and stored at
controlled room temperature (20 - 25 ºC) or under refrigeration (2 - 8 °C). Each combination
of concentration, diluent, and storage was prepared in triplicate. Samples were assayed using
a stability-indicating, reversed-phase high performance liquid chromatography immediately
at time zero and at 24 hours, 48 hours, 7 days, and 14 days. Stability was defined as
retaining 90% - 110% of the initial adenosine concentration. The samples were also visually
inspected against a light back ground for clarity, color, and the presence of particulate matter.
RESULTS
After 14 days, all samples retained 99 - 101% of the initial adenosine concentration. No
considerable change in pH or visual appearance was noted. The stability data indicated no
significant loss of drug due to chemical degradation or physical interactions during storage.

CONCLUSION
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Adenosine solutions of 10 and 50 µg/mL were stable for at least 14 days in 50 mL polyolefin
infusion bags of 0.9% sodium chloride injection or 5% dextrose injection stored at controlled
room temperature and refrigerated conditions.
Key Words: adenosine, stability, concentration, fractional flow reserve

INTRODUCTION:
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Adenosine, an endogenous nucleoside, is clinically used to convert paroxysmal
supraventricular tachycardia (PSVT) to sinus rhythm by slowing the conduction time through
the AV node and by interrupting the reentry pathway.1 In vivo, it is synthesized in the
myocardium and is released in response to increased metabolic oxygen demands and
ischemia. Adenosine administration results in coronary vasodilation and increased blood
flow.2 Its pharmacological properties allows for its use in the measurement of fractional flow
reserve (FFR) in patients with multivessel coronary artery disease who are undergoing
percutaneous coronary intervention (PCI).3,4 FFR indicates stenosis severity by determining
the ratio of the maximal blood flow in a diseased vessel to the maximum blood flow in the
same vessel without stenosis. The calculation of FFR allows clinicians to accurately identify
specific lesions most likely to induce myocardial ischemia.2
Currently, administrations of intravenous and intracoronary adenosine are used in a
cardiac catherization setting to achieve maximal coronary blood flow and determine FFR.
Since adenosine requires continuous infusion administration and is used in an emergency
setting, stability information would be beneficial for cost saving and accelerated medication
delivery time. Two previous stability studies of diluted solutions of adenosine have
demonstrated stability with the following concentrations: 50, 100, 200, and 750 µg/mL.5,6
Because no information is available on the stability of adenosine solutions at lower
concentrations, the purpose of this study was to determine the stability of adenosine 10
µg/mL and 50 µg/mL solutions in 50 mL polyolefin infusion bags containing 0.9% sodium
chloride injection or 5% dextrose injection at controlled room temperature (20 - 25 ºC) or
under refrigeration (2 - 8 °C).

METHODS:
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RP-HPLC:
A Shimadzu model LC-2010A HT HPLC instrumenta with a C18, 4.6x150 mm, 3 µm,
100 A columnb and a guard cartridge systemc with a C18, 4x3 mm cartridge maintained at 40
°C was used for this study. The instrument contained a degasser, autosampler, and UV
detector, set at 259 nm. A stability-indicating reverse phase high performance liquid
chromatography (RP-HPLC) method was created and used. Data collection and processing
was done using Shimadzu LC Solution software. The mobile phase consisted of methanold
and distilled water (7:93 v/v) with 0.1% trifluoroacetic acide. Adenosine was eluted at a flow
rate of 0.5 mL/min after an injection of 10 µL. Under these conditions, adenosine eluted with
an average retention time of 7 minutes.
Five standard solutions of adenosine, with concentrations of 1, 5, 10, 30, and 50 µg/mL,
were prepared from 100 µg/mL stock solution with distilled water and used to establish
linearity r2 > 0.999 of the detector response. The 100 µg/mL adenosine stock solution was
prepared using 10 mg of adenosine powderf in 100 mL volumetric, using distilled water to
make up the volume. These standards were passed through 0.45 µm, 13 mm diameter
disposable nylon syringe filtersg and assayed by RP-HPLC in triplicate on three separate
days. Six sets of filtered standards were frozen in HPLC vials for use at each time point in
the stability study after linearity was established following the first day’s successful runs.
Intra-day and inter-day variability was determined and is depicted in Tables 1 and 2,
respectively.
TABLE 1.
Intraday standard results of adenosine with concentrations of 1, 5, 10, 30, and 50 µg/mL

TABLE 2.
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Interday standard results of adenosine with concentrations of 1, 5, 10, 30, and 50 µg/mL

A forced degradation study was performed to verify that the assay was stabilityindicating, with the ability to resolve degradation products from the parent compound. A 100
µg/mL adenosine stock solution was again used. From this stock solution, four 10 µg/mL
solutions of 10 mL each were prepared using distilled water as the diluents and treated under
separate conditions. Four samples were prepared as follows: sample one was adjusted to pH
2 with 1 M hydrochloric acid and incubated at 60 ºC, sample two was adjusted to pH 12 with
1 M sodium hydroxide and incubated at 60 ºC, sample three was spiked to a concentration of
3% hydrogen peroxide and incubated at 60 ºC, and sample four was spiked to a concentration
of 3% hydrogen peroxide and placed in direct sunlight. RP-HPLC analysis was performed at
time zero and at every 24 hours until at least 10% degradation had occurred, which occurred
by the 72 hour time point. All degradation products were well separated from the parent
drug with retention times shorter than 6-min.

STABILITY STUDY:
The stability of adenosine 10 µg/mL and 50 µg/mL in 0.9% sodium chloride injection or
5% dextrose injection in 50 mL polyolefin infusion bags stored at controlled room
temperature (20 - 25 ºC) and refrigeration (2 - 8 ºC) was tested as follows.
The average overfill volume of three 50 mL polyolefin infusion bags of 0.9% sodium
chloride injection h and 5% dextrose injectioni was determined for the lots and expirations
used for this stability study. The average overfill of the 50 mL IV bag of 0.9% sodium
chloride injection and 5% dextrose injection was 7.3 mL and 6.3 mL, respectively. For the

two strengths being studied, the volume of overfill was withdrawn along with the volume of
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adenosine 3 mg/mL solutionj to be injected. Adenosine 10 µg/mL and 50 µg/mL were
prepared in triplicate in either 0.9% sodium chloride or 5% dextrose and stored at either
controlled room temperature (20 - 25 ºC) or refrigeration (2 - 8 ºC), yielding a total of 24
prepared samples. In addition to this, each diluent was also stored under controlled room
temperature (20 - 25 ºC) or refrigeration (2 - 8 ºC) without adenosine added, four more
samples total, to serve as controls should unexpected results arise. All preparations were
made using aseptic techniques in a class II biological safety cabinetk. At each stability time
point, the samples were visually inspected for clarity, color, and presence of particulate
matter; 2 mL was aseptically withdrawn for pH measurements and 1 mL for RP-HPLC
analysis.
The initial concentration of adenosine in solution was determined using the regression
equation from the calibration curve, Concentration (µg/mL) = 65964/(Peak Area), from the
time zero analyses as depicted in Figure 1. Using the peak areas, % initial concentration
remaining was determined using the average of the triplicate ± standard deviation. Both
initial concentration and percent initial concentration are depicted in Table 3. For this study,
stability was defined as 90% - 110% of the time zero concentration with no significant
changes in visual appearance or pH.
FIGURE 1.
Calibration Curve

TABLE 3.
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Stability of adenosine 10 and 50 µg/mL in either 0.9% sodium chloride injection or 5%
dextrose injection in polyolefin infusion bags stored at two temperatures, refrigeration (2 - 8
°C) or at controlled room temperature (20 - 25 °C).

pH MEASUREMENTS:
For each sampling time, the pH meterl was calibrated with pH 4m and pH 7n buffer
solutions, yielding a slope ≥97% at 25 ºC. The average pH values for each triplicate ±
standard deviation were determined and are depicted in Table 4. For this study, stability was
defined as a pH measurement consistent with the package labels of each component used,
specifically 3.5 to 7.5.1,7,8

TABLE 4.
Stability Study pH Measurements of adenosine 10 and 50 µg/mL in either 0.9% sodium
chloride injection or 5% dextrose injection in polyolefin infusion bags stored at two
temperatures, refrigeration (2 - 8°C) or at controlled room temperature (20 - 25°C).

RESULTS AND DISCUSSION:
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All solutions were visually clear, colorless, and free of particulate matter at all time
points. The initial pH values of the samples were consistent with the acceptable pH ranges
specified in the package insert, i.e. pH 4.5 – 7.0 for 9% sodium chloride injection and pH 3.5
– 6.5 for 5% dextrose injection. There was no considerable change in pH observed
throughout the study as shown in Table 4. All samples retained greater than 90% of the
initial concentration at all time points, suggesting little to no loss of adenosine due to
chemical degradation or physical adsorption to polyolefin infusion bags packaging as shown
in Table 3.
In future studies, it would be beneficial to perform this study with the use of PVC bags,
which are less expensive and more commonly seen in the hospital setting in order to obtain a
complete range of stability data. Alhough polyvinyl chloride (PVC) IV bags were
unavailable at the time of this study, the use of polyolefin infusion bags provides unique
stability data. In recent years, there has been a shift for many hospitals to use DEHP-free IV
bags, as the plasticizer has been shown to have effects on the development of the male
reproductive system and production of normal sperm in young laboratory animals.9
Polyolefin infusion bags consist of a polymer of ethylene and propylene and are latex-free,
PVC-free, and DEHP-free. The plastic container is developed for parenteral medication and
is commonly referred to as PAB® infusion bags.7, 8 The copolymer contains no plasticizers
and exhibits no leachability, which can be considered an advantage when preparing a lowconcentration adenosine formulation.

CONCLUSION:
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Adenosine solutions of 10 and 50 µg/mL concentrations in 50 mL polyolefin infusion
bags of 0.9% sodium chloride injection and 5% dextrose injection were stable when stored in
the refrigerator or at controlled room temperature for a period of up to 14 days.

FOOTNOTES:
a

HPLC 2010A with LCSolutions. Shimadzu Scientific Instruments, Marlborough, MA.

b

c

Luna C18 column (3 µm particle size, 4.6 mm x 150 mm). Phenomenex, Inc, USA.

SecurityGuard Cartridge C18 (3 mm x 4 mm). Phenomenex, Inc, USA.

d

Methanol HPLC Grade. Fisher Scientific, Fair Lawn, NJ, lot 115982.

e

Trifluoroacetic acid, 99%. ACROS Organics, NJ, lot B0517715.

f

Adenosine, 99+%. ACROS Organics, NJ, lot A0263503.

g

13 mm Syringe Filter (0.45 µm, Nylon, Non-Sterile). Fisherbrand, Ireland, lot R9PN60120.

h

0.9% sodium chloride injection in PAB® container (copolymer of ethylene and propylene).
B.Braun Medical Inc.., Irvine, CA, lot J2D929.

i

5% dextrose injection in PAB® container (copolymer of ethylene and propylene). B.Braun
Medical Inc., Irvine, CA, lot J2C904.

j

Adenosine injection 3 mg/ml, USP. APP Pharm, Schaumburg, IL, lot 6003500.

k

ESCO Airstream Class II Biological Safety Cabinet. ESCO Technologies, Hatboro, PA.

l

SevenEasy pH meter. Mettler-Toledo Inc., Columbus, OH.

m

Buffer solution pH 4.00. Fisher Scientific, Fair Lawn, NJ, lot 085812.

n

Buffer solution pH 7.00. Fisher Scientific, Fair Lawn, NJ, lot 084727.
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TABLE 1.
Intraday standard results of adenosine with concentrations of 1, 5, 10, 30, and 50 µg/mL
Concentration
(mcg/mL)
0
1
5
10
30
50

Run #1
0
63068
313430
632797
1964048
3285579

Peak Area
Run #2
Run #3
0
0
63114
62911
315180
316161
635095
634614
1966455 1967198
3294835 3295877

Average
0
63031
314924
634169
1965900
3292097

SD

%CV

106
1383
1212
1647
5669

0.17
0.44
0.19
0.08
0.17
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TABLE 2.
Interday standard results of adenosine with concentrations of 1, 5, 10, 30, and 50 µg/mL
Concentration
(mcg/mL)
0
1
5
10
30
50

2012/05/29
Average
0
63392
315309
635441
1966374
3297544

Peak Area
2012/05/31 2012/06/02
Average
Average
0
0
63031
62325
314924
312673
634169
632286
1965900
1966368
3292097
3291768

Interday
Average
0
62916
314302
633965
1966214
3293803
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Interday
SD

Interday
%CV

542.75
1423.45
1587.31
271.56
3244.06

0.86
0.45
0.25
0.01
0.10
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TABLE 3.
Stability of adenosine 10 and 50 µg/mL in either 0.9% sodium chloride injection or 5%
dextrose injection in polyolefin infusion bags stored at two temperatures, refrigeration (2 8°C) or at controlled room temperature (20 - 25°C).
Concentration
(mcg/mL)

Diluent
(50 mL IV bag)

Storage
(°C)

Actual Initial
Adenosine
Concentration
(mcg/mL)

25

% Initial Concentration Remaining
24 hours

48 hours

7 days

14 days

10.33 ± 0.41

100.4 ± 0.1

101.0 ± 0.0

100.7 ± 0.3

100.1 ± 0.1

5

10.05 ± 0.39

100.4 ± 0.1

100.8 ± 0.2

100.8 ± 0.2

100.1 ± 0.1

25

10.03 ± 0.32

100.4 ± 0.1

100.4 ± 0.1

100.0 ± 0.6

99.2 ± 0.1

5

10.43 ± 0.20

100.0 ± 0.2

100.1 ± 0.1

99.8 ± 0.1

99.7 ± 0.1

25

48.97 ± 1.07

100.1 ± 0.0

100.1 ± 0.8

100.1 ± 0.8

100.1 ± 0.1

5

48.45 ± 0.59

100.2 ± 0.1

100.2 ± 0.0

100.2 ± 0.0

100.0 ± 0.0

25

50.09 ± 1.37

100.1 ± 0.0

100.2 ± 0.1

99.7 ± 0.1

99.7 ± 0.2

5

50.68 ± 1.96

100.0 ± 0.1

100.0 ± 0.1

99.8 ± 0.2

99.8 ± 0.1

NS
10
D5W

NS
50
D5W
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TABLE 4.
Stability Study pH Measurements of adenosine 10 and 50 µg/mL in either 0.9% sodium
chloride injection or 5% dextrose injection in polyolefin infusion bags stored at two
temperatures, refrigeration (2 - 8°C) or at controlled room temperature (20 - 25°C).

Concentration
(mcg/mL)

Diluent
(50 mL IV bag)

pH (Mean ± SD)
24 hours
48 hours
7 days

Storage
(°C)

0 hours

25

4.94 ± 0.21

5.08 ± 0.08

4.95 ± 0.06

4.97 ± 0.02

5.02 ± 0.05

5

4.77 ± 0.03

4.98 ± 0.01

4.90 ± 0.02

4.96 ± 0.02

4.95 ± 0.02

25

4.43 ± 0.03

4.45 ± 0.02

4.43 ± 0.01

4.43 ± 0.00

4.48 ± 0.03

5

4.43 ± 0.01

4.45 ± 0.03

4.42 ± 0.01

4.44 ± 0.02

4.50 ± 0.02

25

4.93 ± 0.01

5.06 ± 0.04

5.00 ± 0.02

5.07 ± 0.02

5.08 ± 0.02

5

4.88 ± 0.02

5.04 ± 0.03

4.97 ± 0.01

5.05 ± 0.03

5.09 ± 0.01

25

4.55 ± 0.01

4.56 ± 0.01

4.54 ± 0.00

4.55 ± 0.01

4.60 ± 0.01

5

4.52 ± 0.03

4.57 ± 0.01

4.53 ± 0.01

4.55 ± 0.01

4.61 ± 0.01

14 days

NS
10
D5W

NS
50
D5W

